Table 6.
Sample type | Assay | Method | Location of work | Study subjects | Time-points |
Plasma | I-FABP, CRP, AGP, TNFα, LBP, sCD14, IGF-1 | ELISA | Zvitambo | All | Baseline, endline |
Peripheral blood leucocytes | Innate immune cell phenotype* | Flow cytometry | Zvitambo | All | Baseline, endline |
Whole blood | Whole Blood Culture with and without LPS | Cell culture, flow cytometry and ELISA | Zvitambo | All | Baseline, endline |
Whole blood | Bacterial binding Assay | Cell culture, flow cytometry | Zvitambo | All | Baseline, endline |
Stool | Myeloperoxidase, neopterin, alpha-1 antitrypsin | ELISA | Zvitambo | All | Baseline, endline |
Urine | Global untargeted metabolomic phenotyping | 1H NMR spectroscopy | Southampton, UK | All | Baseline, endline |
Plasma | Global untargeted metabolomic phenotyping | 1H NMR spectroscopy | Southampton, UK | All | Baseline, endline |
Plasma | Kynurenine:tryptophan ratio, citrulline, essential amino acids, choline | Ultrahigh-performance liquid chromatography tandem mass spectrometry with electrospray ionisation | Southampton, UK | All | Baseline, endline |
Stool | Whole metagenome shotgun sequencing | Illumina HiSeq | Blizard Institute, UK | All | Baseline, endline |
Stool | Metabolic phenotyping of faecal water | 1H NMR spectroscopy | Southampton, UK | All | Baseline, endline |
Urine | Aflatoxin M1 and creatinine | ELISA | Zvitambo | All | Baseline, endline |
*Expression of surface activation markers HLA-DR, CD64 and CD16 on monocytes and HLA-DR, CD64, CD16 and CD62L on neutrophils.
AGP, alpha-1 acid glycoprotein; CRP, C reactive protein; I-FABP, intestinal fatty acid binding protein; IGF-1, insulin like growth factor 1; LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide; NMR, nuclear MR.